ATE183397T1 - Behandlung präkanzeröser läsionen durch muramylpeptide - Google Patents

Behandlung präkanzeröser läsionen durch muramylpeptide

Info

Publication number
ATE183397T1
ATE183397T1 AT94928469T AT94928469T ATE183397T1 AT E183397 T1 ATE183397 T1 AT E183397T1 AT 94928469 T AT94928469 T AT 94928469T AT 94928469 T AT94928469 T AT 94928469T AT E183397 T1 ATE183397 T1 AT E183397T1
Authority
AT
Austria
Prior art keywords
pct
treatment
precancerous lesions
muramylpeptides
cancers
Prior art date
Application number
AT94928469T
Other languages
English (en)
Inventor
Boris Vladimirovich Sh Pinegin
Original Assignee
Peptech Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptech Uk Ltd filed Critical Peptech Uk Ltd
Application granted granted Critical
Publication of ATE183397T1 publication Critical patent/ATE183397T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Silicon Polymers (AREA)
  • Silicon Compounds (AREA)
AT94928469T 1993-10-08 1994-10-05 Behandlung präkanzeröser läsionen durch muramylpeptide ATE183397T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939320820A GB9320820D0 (en) 1993-10-08 1993-10-08 Compounds for medicinal use

Publications (1)

Publication Number Publication Date
ATE183397T1 true ATE183397T1 (de) 1999-09-15

Family

ID=10743251

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94928469T ATE183397T1 (de) 1993-10-08 1994-10-05 Behandlung präkanzeröser läsionen durch muramylpeptide

Country Status (17)

Country Link
US (1) US5877147A (de)
EP (1) EP0722332B1 (de)
JP (1) JP3954644B2 (de)
KR (1) KR100337977B1 (de)
AT (1) ATE183397T1 (de)
AU (1) AU680302B2 (de)
BG (1) BG100476A (de)
CA (1) CA2173322A1 (de)
CZ (1) CZ99796A3 (de)
DE (1) DE69420145T2 (de)
GB (1) GB9320820D0 (de)
HU (1) HUT75530A (de)
IL (1) IL111198A0 (de)
LV (1) LV11595B (de)
SK (1) SK42396A3 (de)
WO (1) WO1995010293A1 (de)
ZA (1) ZA947894B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9413935D0 (en) * 1994-07-11 1994-08-31 Peptech Uk Ltd Use of maramyl peptide compounds
WO1997005889A1 (en) * 1995-08-03 1997-02-20 Slesarev Vladimir I Non-specific vaccination by d-amino-acid containing compounds
NL1014380C2 (nl) * 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.
US7863011B2 (en) * 2000-05-10 2011-01-04 Signe Biopharma, Inc. Screening method for predicting susceptibility to breast cancer
MXPA02011092A (es) 2000-05-10 2004-08-19 David A Sirbasku Composiciones y metodos para demostrar la regulacion del sistema inmune secretor del crecimiento de la celula de cancer que responde a la hormona esteroidea.
US6867238B2 (en) * 2001-06-22 2005-03-15 Gerhard N. Schrauzer Compositions for the treatment and prevention of cancer
US7211258B2 (en) * 2002-04-10 2007-05-01 Protalex, Inc. Protein A compositions and methods of use
US7425331B2 (en) * 2002-04-10 2008-09-16 Protalex, Inc. Protein A methods of use
US7112564B2 (en) * 2003-04-09 2006-09-26 Zylacta Corporation Biodegradable glucosaminemuramyl peptides for apoptosis modulation
US20070185012A1 (en) * 2003-07-10 2007-08-09 Rajadhyaksha V J Glycopeptides for the treatment of als and other metabolic and autoimmune disorders
US8163702B2 (en) * 2006-04-20 2012-04-24 Sciclone Pharmaceuticals, Inc. Treatment of melanoma
US7906486B2 (en) * 2007-02-13 2011-03-15 Sciclone Pharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa
AU2009232504B2 (en) 2008-04-01 2013-04-04 Innate Immunotherapeutics Limited Compositions and methods for treatment of neoplastic disease
NZ571665A (en) * 2008-09-30 2011-01-28 Innate Therapeutics Ltd Compositions and methods for treatment of radiation exposure utilising cross-linked muramyl dipeptide microparticles
RU2571551C1 (ru) * 2015-04-16 2015-12-20 Закрытое акционерное общество "ПЕПТЕК" Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
BR112023018950A2 (pt) 2021-03-19 2024-02-27 Icahn School Med Mount Sinai Composto, composições nanobiológica e farmacêutica, métodos para tratar um distúrbio de proliferação celular, para tratar sepse e para ativar um receptor nod2, processo para fabricação de uma composição nanobiológica e kit

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186194A (en) * 1973-10-23 1980-01-29 Agence Nationale De Valorisation De La Recherche (Anvar) Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
US4370265A (en) * 1974-10-22 1983-01-25 Agence Nationale De Valorisation Water soluble agents effective as immunological adjuvants for stimulating in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
GB1563561A (en) * 1976-06-23 1980-03-26 Daiichi Seiyaku Co Muramyldipeptide derivatives and process for the preparation thereof
SU727647A1 (ru) * 1977-11-02 1980-04-15 Институт биоорганической химии им.М.М.Шемякина Гликопептиды,обладающие противоопухолевой активностью и способ их получени
JPS6033120B2 (ja) * 1977-11-15 1985-08-01 第一製薬株式会社 新規ムラミルジペプチド誘導体
DE2862107D1 (en) * 1977-12-02 1982-11-18 Takeda Chemical Industries Ltd Glucosamine-peptide derivatives and their pharmaceutical compositions
FR2428050A1 (fr) * 1978-06-05 1980-01-04 Anvar Oligomeres de composes du type muramyl-peptide et medicaments les contenant
JPS5519236A (en) * 1978-07-27 1980-02-09 Dai Ichi Seiyaku Co Ltd Muramyl dipeptide derivative
JPS5618996A (en) * 1979-06-21 1981-02-23 Dai Ichi Seiyaku Co Ltd Muramyldipeptide derivative
FI75578C (fi) * 1979-07-25 1988-07-11 Ciba Geigy Ag Analogifoerfarande foer framstaellning av farmakologiskt verkande lipofila fosfatidylmuramylpeptider.
US5189014A (en) * 1979-12-03 1993-02-23 Cowan Jr Fred M Method of treating cellular Fc receptor mediated hypersensitivity immune disorders
US4684625A (en) * 1982-07-08 1987-08-04 Syntex (U.S.A.) Inc. Method for enhancing the anti-infective activity of muramyldipeptide derivatives
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4774085A (en) * 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4774058A (en) * 1985-09-26 1988-09-27 Mehl Ehrenfried L Apparatus for, and methods of, operating upon a fluid
HU205147B (en) * 1989-06-29 1992-03-30 Sandoz Ag Process for producing muramyl dipeptide derivative and pharmaceutical compostions comprising same
WO1993010148A1 (en) * 1991-11-19 1993-05-27 Peptech (Uk) Limited Muramyl compounds for treatment of septic shock

Also Published As

Publication number Publication date
US5877147A (en) 1999-03-02
HUT75530A (en) 1997-05-28
BG100476A (bg) 1996-12-31
ZA947894B (en) 1996-04-09
CA2173322A1 (en) 1995-04-20
JPH09503776A (ja) 1997-04-15
EP0722332B1 (de) 1999-08-18
GB9320820D0 (en) 1993-12-01
JP3954644B2 (ja) 2007-08-08
DE69420145D1 (de) 1999-09-23
KR100337977B1 (ko) 2002-10-09
SK42396A3 (en) 1997-01-08
LV11595B (en) 1997-06-20
AU680302B2 (en) 1997-07-24
WO1995010293A1 (en) 1995-04-20
LV11595A (en) 1996-12-20
HU9600887D0 (en) 1996-06-28
CZ99796A3 (en) 1996-09-11
EP0722332A1 (de) 1996-07-24
DE69420145T2 (de) 1999-12-09
AU7789094A (en) 1995-05-04
IL111198A0 (en) 1995-12-08

Similar Documents

Publication Publication Date Title
ATE183397T1 (de) Behandlung präkanzeröser läsionen durch muramylpeptide
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
GB9407305D0 (en) Pharmaceutical compositions
IL113566A0 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
GR3024667T3 (en) Cosmetical or pharmaceutical compositions comprising deacylated glycerophospholipids for topical use.
ATE152628T1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
HUT77868A (hu) Imidazopiridin-azolidinonok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra
DE69431603D1 (de) Oligopeptide hergeleitet von fragmenten des c-reaktiven proteins
YU45103A (sh) Upotreba sarp/1 za lečenje i prevenciju skleroderme
IL122659A (en) Pharmaceutical compositions for the treatment of dyspeptic symptoms comprising angiotensin ii type receptor antagonists
ATE200624T1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
FI964448A0 (fi) Uusi biologisesti aktiivinen peptidi ja sen valmistus
ATE121422T1 (de) Neue antikoagulatorisch wirksame peptide.
MD980129A (en) Antiherpetic remedy
DE69323191D1 (de) Wasserlösliche retinoide
IT1242475B (it) Agente colinergico, in particolare glicil-p-ammino-piridina-anilide- monoacetato, per il trattamento degli stati di demenza senile.
SE9403861D0 (sv) Novel medicinal use
NO984965L (no) Komponent B som cicatrisant
PT751774E (pt) Derivados de dissulfureto de mercaptoacetilamida hipocolesterolemicos
AU6829396A (en) Compositions and their uses